Summary
Danaher Corporation reported a robust first quarter for 2021, driven by significant revenue growth and strong operating profit performance. Total sales increased by a substantial 58.0% year-over-year, largely attributed to the impactful acquisition of Cytiva, which contributed 34.5% to the revenue increase, and a favorable foreign currency exchange impact of 3.5%. Core sales, excluding acquisitions and currency impacts, demonstrated healthy growth of 20.0%, with an adjusted "core sales including Cytiva" metric showing a 30.0% increase, highlighting the organic strength within the existing businesses and the immediate positive effect of Cytiva. The company saw impressive improvements across its segments, particularly in Life Sciences and Diagnostics, which benefited from increased demand related to COVID-19 testing, research, and vaccine development, alongside a broader recovery in healthcare. Operating profit margins expanded significantly, increasing by 1,300 basis points overall due to higher sales volumes, favorable product mix, cost management, and the accretive effect of acquisitions. Danaher maintains a strong liquidity position, with substantial cash from operations and significant cash reserves, positioning it well for continued investment and strategic initiatives.
Financial Highlights
49 data points| Revenue | $6.86B |
| Cost of Revenue | $2.60B |
| Gross Profit | $4.25B |
| R&D Expenses | $380.00M |
| SG&A Expenses | $1.88B |
| Operating Income | $2.00B |
| Interest Expense | $58.00M |
| Net Income | $1.70B |
| EPS (Basic) | $2.33 |
| EPS (Diluted) | $2.29 |
| Shares Outstanding (Basic) | 713.20M |
| Shares Outstanding (Diluted) | 735.10M |
Key Highlights
- 1Total sales surged by 58.0% to $6.9 billion in Q1 2021, a significant increase driven by the Cytiva acquisition and organic growth.
- 2Core sales (excluding acquisitions and currency) grew by 20.0%, indicating strong underlying business performance.
- 3Life Sciences segment sales more than doubled (115.0% increase) primarily due to the Cytiva acquisition, with core sales including Cytiva growing by 41.5%.
- 4Diagnostics segment experienced robust growth with total sales up 34.0% and core sales up 31.0%, fueled by COVID-19 related testing and recovering lab volumes.
- 5Operating profit margins improved dramatically, expanding by 1,300 basis points to 29.1%, reflecting strong operational leverage and efficiency gains.
- 6The company generated $1.9 billion in operating cash flow, a 127% increase year-over-year, demonstrating strong cash-generating capabilities.
- 7Danaher holds $6.3 billion in cash and cash equivalents as of April 2, 2021, providing significant financial flexibility.